Login / Signup

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.

Jian LiXinhua ZhangYanhong DengXin WuZhichao ZhengYongjian ZhouShirong CaiYanqiao ZhangJun ZhangKaixiong TaoYuehong CuiHui CaoKuntang ShenJiren YuYe ZhouWenxiao RenChenglin QuWanqi ZhaoJin HuWei WangJason YangLin Shen
Published in: The oncologist (2022)
Avapritinib was generally well tolerated and showed marked anti-tumor activity in Chinese patients with GIST bearing PDGFRA D842V mutations and notable efficacy as fourth- or later-line monotherapy (ClinicalTrials.gov Identifier: NCT04254939).
Keyphrases
  • open label
  • phase ii
  • clinical trial
  • phase ii study
  • squamous cell carcinoma
  • phase iii
  • small cell lung cancer
  • locally advanced
  • study protocol
  • liver metastases
  • radiation therapy